EcoDrugPlus

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOJAG00000009615
Gene Symbol: PTH1R
1 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSOJAG00000017061
Gene Symbol: PPARG
1 Cross references
386 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSOJAG00000013653
Gene Symbol: PPARAA
1 Cross references
383 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSOJAG00000007892
Gene Symbol: PPARAB
1 Cross references
396 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSOJAG00000016935
Gene Symbol: PPARDB
1 Cross references
392 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOJAG00000012146
Gene Symbol: PIK3CA
1 Cross references
208 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOJAG00000021116
Gene Symbol: PIK3CA
1 Cross references
181 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSOJAG00000014934
Gene Symbol: PIK3CB
1 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSOJAG00000022967
Gene Symbol: PIK3CD
1 Cross references
211 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSOJAG00000009391
Gene Symbol: PDE10A
1 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSOJAG00000005103
Gene Symbol: PDE3A
1 Cross references
195 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSOJAG00000005114
Gene Symbol: PDE3A
1 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).